Despite this promise, several critical limitations remain: No large-scale, randomized controlled human trials to confirm efficacy, safety, or long-term impact Toxicology and pharmacokinetic data are lacking, especially for chronic use or high-dose regimens Only one stereoisomer (all-L form) has been tested
The first strategy is by inhibiting the activity of the dipeptidyl peptidase-4 by DPP-4 inhibitors
Semaglutide Start: 0.25 mg once weekly Increase to: 0.5 mg weekly Then: 1 mg weekly Maintenance: up to 1.72.4 mg weekly, depending on tolerance Tirzepatide Start: 2.5 mg once weekly Increase to: 5 mg weekly Then: 7.5 mg Then: 10 mg Then: 12.5 mg Maximum: 15 mg weekly Retatrutide (Currently follows dosing schedules used in clinical studies.) Start: 12 mg once weekly Gradually increase to: 4 mg Then: 8 mg Then: 12 mg weekly Your provider will determine the safest dose progression based on your response and tolerance
Siuzdak, Identification of bioactive metabolites using activity metabolomics
Bogaz EA, Maranhao AS, Inoue DP, Suzuki FA, Penido NO